Medworxx Solutions Inc. (“Medworxx”) (TSX VENTURE:MWX) is pleased to announce two new appointments to the Medworxx board of directors and the creation of a corporate advisory committee. Mr. Har Grover and Mr. Steve Garrington have joined the Medworxx Board of Directors.
Board of Directors
Har Grover is an entrepreneur, senior executive and strategist with 30 years of corporate development experience in healthcare and technology. Mr. Grover's international experience includes; merger and acquisitions, strategic alliances, and joint ventures into new markets such as Canada, United States, India, Japan, and Russia. Mr. Grover is currently the founder and managing director of Nucleus GC, a professional services and investment company in Toronto specializing in life sciences markets. Mr. Grover has over 10 years of experience on corporate and advisory boards including: Chair of Armour Therapeutics and Chair of Crohn's and Colitis Canada.
Based in Australia, Steve Garrington brings 30 years of Healthcare IT business experience to his role on the Medworxx board. Mr Garrington has held leadership positions at several international software companies including; Misys, Torex, Ascribe, IBA Health, and iSOFT. Mr. Garrington is currently Vice President International at InterSystems, a privately owned software technology and applications company headquartered in Cambridge, USA. Mr. Garrington's expertise has been developed in a range of markets including Asia Pacific, Continental Europe, Middle East, North America and the United Kingdom.
Concurrent with the appointment of Mr. Grover and Mr. Garrington, Medworxx is announcing the resignations of Mrs. Renah Persofsky and Mr. Sam Marafioti from its board of directors. Mrs. Persofsky and Mr. Marafioti have been valued members of the Medworxx board since its inception nine years ago. George Elliott, Medworxx board chairman, commented on the changes to the board, “I would like to thank Renah and Sam for their continued support and I am happy to have their expertise on our newly created advisory committee. I would also like to welcome Har and Steve to the Medworxx board, their wealth of strategy experience in the healthcare IT sector will be an asset as we continue to expand into new territories.”
Corporate Advisory Committee
The newly created Medworxx advisory committee has been created to assist with the ongoing expansion strategy into international markets. The advisory committee will consist of Mrs. Renah Persofsky, Mr. Sam Marafioti, Mrs. Frances Pennell and Dr. Myrna Francis.
Mrs. Pennell (retired) has over 35 years of experience working in the healthcare industry, including 21 years as a partner with PricewaterhouseCoopers (PwC) USA, where she guided their Healthcare Performance Improvement consulting practice primarily in the US market. Mrs. Pennell has worked extensively with boards of directors, senior leaders and medical personnel to guide decisions for achieving efficient and effective healthcare operations and financial stability.
Completing the committee’s list of seasoned professionals is Dr. Myrna Francis, Ph.D, Medical Science. Dr. Francis (retired) has extensive public and private sector experience in the healthcare and technology industries, spanning the international marketplace - Canada, US, Europe. Dr. Francis served as president and CEO of Canada Health Infoway during its start-up phase. Dr. Francis was also the VP, Global Healthcare Industry for CGI, general manager, Health and Life Science Industry group and Strategic Business Development at IBM and was a partner at CSC Healthcare Group. Currently, she is an advisor to the MaRS Discovery District.
“Har, Steve, Fran and Myrna are welcomed assets to Medworxx; they have joined an illustrious team. It is exciting that we have attracted international Healthcare IT operational expertise to help advise us at both the board and advisory level. As we continue on our journey of international expansion this will be extremely helpful,” says Dan Matlow, President and CEO, Medworxx.
The company is reporting the grant of 370,000 options to certain officers, directors and employees of the company, pursuant to the company’s employee stock option plan at an exercise price of $0.35 per share.
Medworxx delivers health information solutions to over 350 hospitals internationally; including Canada, United States and United Kingdom. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Clinical Criteria – flagship of Medworxx Patient Flow that includes electronic bed board and independent assessment components – currently serves over 35% of the acute care beds in Canada. Founded in 2004, Medworxx is based in Toronto, ON, and publicly traded on the TSX Venture Exchange: MWX. Visit: www.medworxx.com
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Health Care Industry
- Investment & Company Information
- board of directors